Blood Thinner Shows Promise Against Osteoarthritis

Early animal studies suggest the anticoagulant dabigatran may slow cartilage damage and ease knee inflammation in osteoarthritis.

Updated on Nov. 11, 2026 in Arthritis

Clean laboratory bench with a row of clear glass dishes and a microscope in soft daylight from a high window.
Preclinical research found the blood thinner dabigatran slowed cartilage damage and eased knee inflammation in osteoarthritis-affected monkeys and mice, though results remain preliminary. AI Illustration. Upload story photo >

Live Poll

Would you try a drug that slows osteoarthritis if one became available?

Researchers reported that dabigatran, a blood-thinning drug commonly used to prevent clots and strokes, reduced cartilage damage and improved knee mobility in monkeys and mice with osteoarthritis. The findings are preliminary and come from animal studies only.

Why it matters

Osteoarthritis affects more than 500 million people worldwide, and no approved drugs halt or slow its progression. Clinical trials of drugs targeting TNF-alpha or IL-1-beta have been unsuccessful, making a new therapeutic direction significant.

The study used eight monkeys, with four receiving daily dabigatran in their food and the rest serving as controls, and cartilage thickness and knee range of motion were measured after seven months. Whether these animal results will hold in people has not yet been tested.

The players

Yale University

A private research university in New Haven, Connecticut, where lead researcher Chuan-Ju Liu is based.

University of Oxford

A public research university in England whose researcher Tonia Vincent commented on the findings.

The details

Researchers surgically removed part of the cartilage in the left knee joints of eight monkeys to mimic the wear that triggers osteoarthritis. A month later, four monkeys began a daily dabigatran dose mixed into their food while the others ate their usual diet. The findings suggest dabigatran could slow osteoarthritis progression in people, though researchers plan to develop drugs targeting TNF-alpha and IL-1-beta without reducing blood clotting.

Timeline

  1. A month after surgery, monkeys began the daily dabigatran or control diet.

  2. After seven months, MRI scans showed thicker cartilage in the dabigatran-treated monkeys.

Health Landscape

Earlier osteoarthritis trials targeting TNF-alpha and IL-1-beta failed, potentially because these molecules compensate for each other when one is blocked. This anticoagulant approach departs from that line of research by aiming at a different pathway while avoiding the clotting-related effects that define dabigatran's current use.

Dabigatran is currently used to prevent blood clots, not to treat joint disease, so the findings do not change current treatment options. Anyone with osteoarthritis should continue following guidance from their own clinician until human studies are available.

The takeaway

Animal results are an early step, and a drug that prevents clots carries bleeding risks that would need careful evaluation before any use in osteoarthritis. Human trials will be required to show whether slowing cartilage damage is safe and effective.

Further reading

For broader context on joint conditions, explore our Arthritis coverage.

Source note: This article includes information reported by New Scientist.

Live Poll

Would you try a drug that slows osteoarthritis if one became available?